Metagenomic Markets. Global Market Analysis with Forecasts by Applications, Technologies, Product and User. With Executive and Consultant Guides. 2025 to 2029
Unlimited growth potential? A Game Changer? It is not exaggeration. Metagenomic assays could change the way medical treatment is done. Learn all about it in this new research report.
The role of genetics in health and disease is just now being understood. This new knowledge, combined with lower costs is driving a new type of genetic testing. Metagenomic Testing looks at all the genetic material in a sample. In the process it learns about infection, cancer, antimicrobial resistance, and the patient genome. It's a whole new approach. Chronic infection? Find out the real culprits. Secrets of the microbiome and gut health? Metagenomics has the answers. In everything from human medical treatment to wastewater studies this new approach is creating startling answers. And finding new kinds of organisms and pathogens in the process. Already some minor medical miracles have been accomplished. This report looks at the technology, the applications, the users and the types of products that will be sold. The report includes detailed breakouts for 14 countries and 5 regions.
Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.
All report data is available in Excel format on request.
Make investment decisions and valuations with confidence using the latest data.
Table of Contents
1. Market Guides
1.1. Strategic Situation Analysis
1.2. Guide for Executives and Business Development Staff
1.3. Guide for Management Consultants and Investment Advisors
2. Introduction and Market Definition
2.1. What is Metagenomics?
2.2. Market Definition
2.2.1. Revenue Market Size.
2.2.2. Clinical
2.2.3. Microbiome
2.2.4. Agricultural
2.2.5. Environmental & Other
2.3. Methodology
2.3.1. Methodology
2.3.2. Sources
2.3.3. Authors
2.4. Perspective: Healthcare and the IVD Industry
2.4.1. Global Healthcare Spending
2.4.2. Spending on Diagnostics
2.4.3. Important Role of Insurance for Diagnostics
2.5. Chromosomes, Genes and Epigenetics
2.5.1. Chromosomes
2.5.2. Genes
2.5.3. Epigenetics
3. Market Overview
3.1. Players in a Dynamic Market
3.1.1. Academic Research Lab
3.1.2. Diagnostic Test Developer
3.1.3. Instrumentation Supplier
3.1.4. Chemical/Reagent Supplier
3.1.5. Pathology Supplier
3.1.6. Independent Clinical Laboratory
3.1.7. Public National/regional Laboratory
3.1.8. Hospital Laboratory
3.1.9. Physicians Office Lab (POLS)
3.1.10. Audit Body
3.1.11. Certification Body
3.2. Metagenomics Applications
3.2.1. Clinical Metagenomics
3.2.2. Diagnostic Use
3.2.3. Syndromic Multiplex vs. Metagenomic Testing
3.2.4. Antimicrobial Resistance
3.2.5. Managing the Microbiome
3.2.6. Public Health Use
3.3. Clinical Industry Structure
3.3.1. Hospital's Testing Share
3.3.2. Economies of Scale
3.3.3. Hospital vs. Central Lab
3.3.4. Physician Office Lab's
3.3.5. Physician's and POCT
4. Market Trends
4.1. Factors Driving Growth
4.1.1. A New Approach to Diagnostics
4.1.2. The Aging Effect
4.1.3. The Known and the Unknown
4.1.4. A Research Bonanza
4.2. Factors Limiting Growth
4.2.1. Increased Competition Lowers Price
4.2.2. Lower Costs
4.2.3. Testing usage analysis curtailing growth
4.2.4. Wellness has a downside
4.3. Instrumentation, Automation and Diagnostic Trends
4.3.1. Traditional Automation and Centralization
4.3.2. The New Automation, Decentralization and Point of Care
4.3.3. Instruments Key to Market Share
4.3.4. Bioinformatics Plays a Role
4.3.5. PCR Takes Command
4.3.6. Next Generation Sequencing Fuels a Revolution
4.3.7. NGS Impact on Pricing
4.3.8. Whole Genome Sequencing, A Brave New World
4.3.9. Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10. Shifting Role of Diagnostics
5. Metagenomics Recent Developments
5.1. Recent Developments
5.1.1. Importance of This Section
5.1.2. How to Use This Section
5.2. Delve Bio Showing Delivers Greater Diagnostic Yield